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Abstract Although the benefits of using the left inter-
nal mammary artery to bypass the left anterior descending
artery (LAD) have been extensively ascertained, freedom
from major cardiovascular events and survival after coro-
nary artery bypass grafting (CABG) also correlate with the
completeness of revascularisation. Hence, careful selection
of the second-best graft conduit is crucial for CABG suc-
cess. The more widespread use of saphenous vein grafts
contrasts with the well-known long-term efficacy of multi-
ple arterial grafting, which struggles to emerge as the pro-
cedure of choice due to concerns over increased technical
difficulties and higher risk of postoperative complications.
Conduit choice is at the discretion of the operator instead of
being discussed by the heart team, where cardiologists are
not usually engaged in such decisions due to a hypotheti-
cal lack of technical knowledge. Furthermore, according to
the ESC/EACTS guidelines, traditional CABG remains the
gold standard for multi-vessel coronary artery disease with
complex LAD stenosis, but hybrid procedures using per-
cutaneous coronary intervention for non-LAD targets could
combine the best of two worlds. With the aim of raising the
cardiologist’s awareness of the surgical treatment options,
we provide a comprehensive overview of the anatomical,
functional and clinical aspects guiding the decision-making
process in CABG strategy.
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Introduction
The choice of the optimal revascularisation strategy in pa-
tients with multi-vessel disease has been a great challenge
for worldwide interventional cardiologists and surgeons for
a long time. In the last 15 years many large-scale ran-
domised trials have compared multi-vessel percutaneous
coronary intervention (PCI) with coronary artery bypass
grafting (CABG) in terms of long-term survival rate, treat-
ment efficacy and incidence of major adverse cardiovascular
events (MACE) [1–3].
Lately, technological progress and new findings in phar-
macological therapy have led to a significant improvement
in clinical outcomes following PCI. The use of new-gen-
eration drug-eluting stents (DES), glycoprotein IIb/IIIa re-
ceptor inhibitors and bivalirudin produced an undoubted re-
duction in restenosis, ischaemic and bleeding complication
rates [4–8]. Furthermore, intensive medical management
and widespread implementation of cardiovascular preven-
tion have led to a better control of coronary artery disease
(CAD) progression.
Despite such significant improvements, European Soci-
ety of Cardiology/European Association for Cardio-Tho-
racic Surgery (ESC/EACTS) guidelines still recommend
patients with less extensive CAD be treated with PCI, while
those with left main or three-vessel disease, particularly
when the proximal left anterior descending artery (LAD) is
involved, be diverted to CABG [9].
The selection of the graft conduit is influenced by vari-
ous factors and is crucial for CABG success, affecting sur-
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vival, freedom from myocardial infarction, symptoms and
re-interventions, and correlating with patient outcome [10].
The choice of conduit for CABG seems to be still at
the discretion of the operator instead of being discussed by
the heart team, and this is probably why specific guidelines
have been recently published on this subject [11]. There-
fore, although cardiologists should have an important role
in selecting the most appropriate conduits together with the
surgeon, they are usually not deeply involved due to a hy-
pothetical lack of technical knowledge.
With the aim of raising the cardiologist’s awareness of
the surgical treatment options, we provide a comprehensive
overview of the anatomical, functional and clinical aspects
guiding the decision-making process in CABG strategy.
Conduit classification
The first choice that operators are called to make is whether
to use a venous or an arterial conduit. In general, the main
advantage of arterial grafts is their superior long-term pa-
tency compared with saphenous vein grafts (SVGs) and,
accordingly, arterial grafts are more indicated in younger
patients or in those who have a life expectancy of more than
10 years, which is beyond the benefit of SVGs [12–14].
On the other hand, the technique of arterial grafting is
more challenging and time-consuming, and therefore ve-
nous grafting is preferred in emergency situations and for
patients with a higher operative risk.
While vein grafts act merely as conduits, arterial grafts
have the ability to adapt to different demands of blood sup-
ply and show specific functional properties that will be
subsequently discussed. The structure of the arteries dif-
fers in elastic and muscular composition, thus some are
more reactive to vasoconstrictors than others. From this
assumption, derived from extensive experiments on vasore-
activity, a functional classification for arterial grafts into
three subtypes was proposed by He and Yang [15]: type I,
somatic arteries; type II, splanchnic arteries; and type III,
limb arteries. Due to the higher degree of smooth muscle
cells over elastic fibres, type II and III arteries show higher
contractility and are prone to spasm [15, 16].
Left internal mammary artery
It has long been accepted that using the left internal mam-
mary artery (LIMA) to bypass the left main or the LAD is
the gold standard, especially since it is the most important
factor in improving survival and freedom from MACE in
patients undergoing CABG [17]. Indeed, the use of LIMA
to LAD ranks as the only class I recommendation regarding
CABG conduits in the current ESC/EACTS guidelines on
myocardial revascularisation [9]. It is beyond doubt that the
LIMA is a durable conduit: when used as a coronary graft it
is superior not only to SVGs, but also to other arterial grafts
in terms of lower tendency to vasospasm and enhanced en-
dothelial function as well as nitric oxide and prostacyclin
release [18]. These features confer to it an extreme resis-
tance to atherosclerosis [17], leading to better short-term
and long-term outcomes [17–19]. Above all, the >90% ten-
year patency of LIMA grafting is very noteworthy [14, 19,
20].
However, one question arises: what is the biologi-
cal mechanism behind such peculiar resistance to the
atherosclerotic process? The LIMA is a transition artery
that combines some microscopic features of large vessels,
such as the elasticity of the aorta, with others from medium-
sized vessels, such as the abundance of smooth muscle cells
of coronary arteries. The cross-sectional size of the LIMA
measures 1.9 to 2.6 mm with a wall thickness of 180 to 430
microns [21]. The predominant layer in the LIMA is a thin
tunica media, which consists of collagen and smooth mus-
cle cells aligned circumferentially in between the elastic
layers, while a muscular component is barely represented
[21, 22]. These structural features are the determinants
of wall stiffness [21], but also allow compliance at high
pressure and, together with the small size of the vessel,
help to keep a laminar blood flow, avoiding turbulence,
which is a known trigger of thrombotic and atherosclerotic
processes. Furthermore, the LIMA has a flow rate much
more similar to that of the LAD compared with what SVGs
display, resulting in a minor risk of graft thrombosis. The
intima of the LIMA consists of endothelium with few
fenestrations and low intercellular junction permeability,
which inhibits cellular migration and prevents lipoproteins
from entering the sub-endothelial space leading to intimal
hyperplasia and atheroma [14]. Such endothelial cells
are also rich in heparin sulphate, endothelial nitric oxide
synthase (eNOS) and prostacyclin, which contribute to the
antithrombotic properties, enhance endothelial homeostasis
and protect from atherosclerosis [21]. The pivotal role of
the eNOS in atherogenesis inhibition was demonstrated
by in-vitro immunohistochemical studies conducted by He
and colleagues [23]. They hypothesised a connection be-
tween the superior long-term performance of the internal
mammary artery (IMA) and the higher expression level of
eNOS in its endothelial cells compared with other arterial
grafts. Therefore, besides supplying blood flow to the dis-
eased coronary vessel, the LIMA graft has the peculiarity
of influencing the pathophysiology of the atherosclerotic
plaque.
Finally, there are very few contraindications to the use
of the LIMA, such as significant disease of the subclavian
artery, extreme chest deformities, emergency situations and
previous chest radiotherapy [24].
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Saphenous vein graft
Since first used for CABG in the early 1960s, SVGs have
extensively demonstrated the benefit of surgical revascular-
isation. However, their fast atherosclerotic degeneration, as
compared with the native coronary arteries and with arterial
grafts, raised serious concerns about their widespread use.
These were confirmed by the demonstration of 15–20%
probability of occlusion at 1-year follow-up, and up to
40–50% at 10-year, with a graft attrition rate of 1–2% per
year in the first six years and 4% per each subsequent year
[20].
Different causes seem to be responsible for SVG fail-
ure at different time points. Within the first month from
implantation, the principal mechanism involved seems to
be graft thrombosis, as a direct consequence of endothe-
lial disruption and cell loss caused by mechanical trauma
during the graft harvesting, preparation, and insertion pro-
cesses, even if correctly performed [21, 25]. Indeed, har-
vested SVGs may show large thrombogenic defects with
exposed collagenous fibrils [26]. Endothelial injury is also
perpetrated by haemodynamic stress on the vein wall sud-
denly subjected to arterial pressure and pulsatile flow [25],
which stretches SVGs to a much larger diameter (rang-
ing from 3.1 to 8.5 mm) than the LIMA [14]. However,
in contrast with what is observed in the LIMA, the vein
wall shows poor elastic recoil and increased stiffness [21],
subsequently producing turbulence of blood flow and sig-
nificant reduction of mean blood velocity [14, 20, 21]. The
presence of intact venous valves may also be a predisposing
factor [20, 21]. Furthermore, if not completely occlusive,
thrombotic material is progressively organised into fibrotic
tissue leading to smooth muscle cell migration and prolif-
eration, which are the basis of intimal hyperplasia. Intimal
hyperplasia is defined as the accumulation of smooth mus-
cle cells and extracellular matrix (proteoglycans and type-I
and type-III collagen) in the intimal compartment and rep-
resents the major cause of graft disease between one month
and one year after implantation [14, 20]. These structural
changes in the vein wall pave the way to the development of
atherosclerosis, the predominant process of SVGs attrition
in the subsequent years [14, 20]. Atherosclerotic plaques
in SVGs tend to be diffuse, friable, poorly calcified and
characterised by fibroatheroma that usually presents with
large necrotic cores, rich in inflammatory and foam cells,
and with a very thin fibrolipidic cap, compared with arte-
rial atherosclerosis, making the plaque more susceptible to
rupture [20]. It is also important to highlight that SVGs are
often seriously diseased before being harvested and opera-
tors frequently neglect this. Pre-existing intimal hyperplasia
due to phlebosclerosis affects up to 95% of saphenous veins
after the sixth decade of life [25].
Radial artery
The only viable strategy to avoid vein graft disease is to
utilise autologous arterial grafts rather than SVGs when-
ever possible. Several arteries have been investigated and
the radial artery (RA) is probably the most utilised. First
used in 1974 by Carpentier and colleagues, the RA as coro-
nary graft was soon abandoned due to excessive tendency
toward profound vasospasm and resultant high graft failure
rates [22]. The structure of the RA presents a continu-
ous intima of endothelial cells, a single elastic lamina and
a thick tunica media of smooth muscle cells, which ex-
plains its predisposition to spasm. Even though the RA
shows a higher incidence of atherosclerosis compared with
the LIMA [27], it seems to be provided with mechanisms
that increase blood flow and prevent the development of
atherosclerotic plaque [13, 20]. The endothelial cells of
the RA seem to express lower levels of eNOS than those
of the IMA, which is linked to lower nitric oxide release
and might be related to the inferior long-term patency rate
of the RA compared with the IMA [23]. The RA is one
of the two arteries of the forearm and, because of its su-
perficial and accessible location, can be easily harvested
and its length usually allows all coronary territories to be
reached. The Radial Artery Versus Saphenous Vein Pa-
tency Randomised Trial showed that RA grafts, similarly
to LIMA grafts, are free of late graft attrition, at least at
5-year follow-up [28]. The Radial Artery Patency Study
confirmed lower functional occlusion rates of RA grafts at
1 year and significant lower frequency of complete graft
occlusion at 5-year angiographic follow-up compared with
SVGs [29]. Atherosclerotic disease of the RA before har-
vesting may limit its use in older patients, but age should
not represent an exclusion criterion per se [30]. In many
catheterisation labs, the RA is unquestionably the primary
vascular access for performing coronary angiographies. On
this issue, there are still concerns whether the procedures
of puncturing, sheath insertion and retrieval at the time of
the diagnostic angiography may affect RA patency if used
later for CABG [31, 32]. A known limitation is represented
by possible hand circulatory disorders, ranging from clau-
dication to resting pain or even gangrene, in case of insuf-
ficiency of the ipsilateral ulnar artery. Despite the frequent
use of the Allen test to evaluate hand circulation before
graft removal, around 10% of patients may still develop
mild hand ischaemia after RA harvest [33]. Haemodialysis
may also be considered a contraindication to RA harvest
due to possible need of upper limb dialysis access [34]. As
for other arterial grafts, the RA is very sensitive to compet-
itive flow: the 2011 American College of Cardiology Foun-
dation/American Heart Association guidelines state that the
use of the RA is reasonable when grafting left-sided coro-
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Table 1 Specific factors influencing the choice of the second-best graft conduit
Conduit Advantages Main concerns Contraindications




Easily damaged during harvesting
Previous vein sclerotherapy or vein removal
Ongoing (or previous) phlebitis
RA Easy harvesting





Need of upper limb haemodialysis
GEA In situ use for inferior wall Challenging harvesting technique
Tendency to spasm
Target stenosis <90%
Disease of descending aorta
Abdominal surgery impairment




Right subclavian artery disease
Extreme chest deformity
SVG saphenous vein graft, RA radial artery, GEA right gastro-epiploic artery, RIMA right internal mammary artery
arteries with critical stenoses (>90%) that perfuse the left
ventricle (class IIb) [35].
Gastroepiploic artery
More recently, the right gastroepiploic artery (GEA) has
also been used as a coronary bypass conduit and has been
recognised as a suitable and reliable alternative. The GEA
is a branch of the gastroduodenal artery that runs parallel
to the greater curvature of the stomach, but may present
a wide range of anatomical variants. The proximal portion
of the GEA usually measures 2.5 to 3 mm in diameter and
in most cases remains greater than 1.5 mm in the middle of
the greater curvature. Suma and colleagues, in their experi-
ence with GEA grafting, describe a 5-year patency rate of
85.5% [36], implying a significant durability of the GEA
graft, which seems to have a low incidence of atheroscle-
rosis and sufficient flow capacity to be used as CABG [36,
37]. The in situ GEA easily reaches the inferior wall of
the myocardium without stretching and appears particularly
suitable for anastomosis to the posterior descending artery
or to the proximal right coronary artery [38]. However,
harvest of the GEA usually requires a trans-diaphragmatic
approach or extra-abdominal incision, which may increase
operative time and expose the patient to additional com-
plications. Laparoscopic harvesting may be possible, but
is reserved for selected cases and is not part of common
clinical practice. Furthermore, performing an angiography
of an in situ GEA is definitely more challenging than any
other graft due to its anatomical location. Contraindications
include disease of the descending aorta and not severe nar-
rowing of a dominant right coronary artery [12, 24].
Right internal mammary artery
The demonstrated successful performance and durability of
the LIMA graft led many surgeons to believe that the same
benefits could also apply to the right internal mammary
artery (RIMA). Indeed, in a vast meta-analysis of 27 ob-
servational studies by Weiss et al., a significant increase
in long-term survival was reported in patients undergoing
bilateral mammary artery (BIMA) grafting when compared
with the patients undergoing lone LIMA grafting [39]. Nev-
ertheless no randomised controlled trials have been included
in such meta-analyses and it remains unclear whether this
advantage is directly dependent on the use of the BIMA
or should be simply ascribed to the already demonstrated
benefits of using arterial conduits. As a matter of fact,
BIMA grafting represents only 4–12% of all CABG proce-
dures over the more traditional use of the LIMA with SVGs
[39]. Moreover, recent evidence suggests that BIMA graft-
ing rates are higher in Europe than in the USA (25 vs 10%)
Table 2 Quantification of aspects influencing the choice of the
second-best graft conduit
Features SVG RIMA RA GEA
Attrition rate ++++ + ++ ++
Tendency to vasospasm + ++ ++++ +++
Failure if target stenosis
<70%
+ ++ ++ +++
Operative time + +++ ++ +++
Resistance to harvesting
trauma
+ +++ ++ ++
Nitric oxide and prosta-
cyclin release




++ – + +
Flow reserve – +++ ++ +++
SVG saphenous vein graft, RA radial artery, GEA right gastro-epiploic
artery, RIMA right internal mammary artery
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Table 3 The 2015 Society of Thoracic Surgeons (STS) guidelines on arterial conduits for CABG
Recommendations COR LOE
The IMA should be used to bypass the LAD artery when bypass of the LAD is indicated I B
As an adjunct to LIMA, a second arterial graft (RIMA or RA) should be considered in appropriate patients IIa B
Use of BIMA should be considered in patients who do not have an excessive risk of sternal complications IIa B
As an adjunct to LIMA to LAD (or in patients with inadequate LIMA grafts), use of a RA graft is reasonable
when grafting coronary targets with severe stenoses
IIa B
When RA grafts are used, it is reasonable to use pharmacologic agents to reduce acute intraoperative and peri-
operative spasm
IIa C
Use of arterial grafts (specific targets, number, and type) should be a part of the discussion of the heart team in
determining the optimal approach for each patient
I C
COR class of recommendation, LOE level of evidence, ITA internal thoracic artery, LAD left anterior descending artery, LIMA left internal
mammary artery, RIMA right internal mammary artery, BIMA bilateral internal mammary artery, RA radial artery
Table 4 Patency data from recent comparative studies among arterial conduits for CABG










Deb [29] 2012 269 7.7 ± 1.5 81.4 91.1 – –
Goldman [52] 2011 733 1 89 89 – –
Suma [36] 2007 124 5–17 68 – – 87
Hayward [53] 2011 214 5.5 84.7 92.2 – –
Collins [28] 2011 104 5 77 90 – –
Hwang [54] 2013 566 5 – – 92.7 89.6
SVG saphenous vein graft, RA radial artery, RIMA right internal mammary artery, RGEA right gastroepiploic artery
[40]. Concerns about the use of BIMA grafting are mostly
connected to a potential increase of perioperative morbidity
and mortality (possibly depending on increased duration of
surgical operation) and a higher probability of developing
deep sternal wound infections or dehiscence [41]. Deep
sternal wound infections can be a serious, life-threatening
condition due to the damaging of the sternal microcircu-
lation occurring during the harvesting process. In fact, si-
multaneous harvesting of both IMAs may impair sternal
perfusion and compromise the wound healing process, es-
pecially in patients suffering from diabetes mellitus, chronic
obstructive pulmonary disease or obesity [41]. Careful pa-
tient selection and harvesting skeletonised IMAs, which
seems to preserve sternal microcirculation over the tradi-
tional pedicled technique, may minimise this complication
[39, 42]. The Arterial Revascularisation Trial (ART) is
an ongoing randomised trial comparing BIMA with single
IMA CABG: initial results from this study have not shown
significant difference between the two groups in terms of
survival or MACE incidence at 30-day or at 1-year. On the
other hand, sternal wall reconstruction was more frequently
required in the BIMA group (1.9% vs 0.6%) [41].
Grafting and stenting: hybrid coronary artery
revascularisation
An appealing option for the treatment of multi-vessel CAD
(MVCAD) is represented by hybrid coronary artery revas-
cularisation (HCAR). This technique combines the long-
term benefits of LIMA grafting on the LAD and the min-
imal invasiveness of PCI on non-LAD territories. HCAR
aims to minimise surgical-related impact on quality of life
by performing a LIMA-LAD graft during off-pump mini-
sternotomy, followed by implantation of DES in non-LAD
lesions. This approach is typically destined for patients at
high risk of MACE, affected by MVCAD with a complex
LAD lesion and non-complex non-LAD lesions, who oth-
erwise would more likely undergo traditional CABG [43].
Therefore, HCAR normally allows a quicker recovery after
surgery, generating less perioperative morbidity and a lower
incidence of adverse events connected to cardiopulmonary
bypass and full sternotomy [43, 44]. However, according
to the latest ESC/EACTS guidelines on myocardial revas-
cularisation [9], the treatment of choice for MVCAD with
important and/or complex stenosis of the LAD, and with
acceptable surgical risk, remains traditional CABG.
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Discussion
The choice of conduit is of outmost importance for the long-
term success of CABG. The benefits of using the LIMA
to bypass the LAD have been extensively ascertained and
explain the pivotal role that this graft nowadays holds in
common surgical practice. Although the use of the LIMA
to the LAD is essential, MACE-free survival after CABG
also correlates with the completeness of myocardial revas-
cularisation [10] and, for this reason, the choice for the
second-best graft is a constant source of debate (Table 1
and 2). Some studies reported a better MACE-free sur-
vival rate with the use of the RIMA over the RA as second
arterial graft [45, 46], while others support the RA over
the RIMA, which is considered to be excessively prone
to postoperative complications in certain groups of patients
[41, 45]. The GEA gave excellent long-term results as third
arterial graft [47], but despite its good patency rates, it is
burdened by a challenging harvesting process and concerns
about complications. The more widespread use of SVGs
contrasts with the well-known long-term efficacy of multi-
ple arterial grafting. Indeed, several clinical trials suggest
that arterial revascularisation should be encouraged [13, 16,
22, 29, 34, 45, 46, 48–51]. In Table 3 we report the latest
recommendations of Society of Thoracic Surgeons guide-
lines on arterial conduit choice [11] and in Table 4 evi-
dence of patency in different conduits from recent studies
[28, 29, 36, 52–54]. Locker et al. [13] describe a linear
correlation between late graft patency and survival: the ab-
sence of arterial grafts was recognised as an independent
predictor of late death, which relates to their excellent pa-
tency rates compared with SVGs, assessed around 95.5% at
12 weeks and 88.9% at 12 months for RA and similar for
other arterial conduits [18]. In spite of its demonstrated ben-
efits, multiple arterial revascularisation is not routinely used
and struggles to establish itself as a procedure of choice.
The reasons behind the low use of arteries as second graft
lie in the concerns of increased technical difficulties and
higher risk of postoperative complications. Furthermore,
arterial grafts can be severely damaged by native compet-
itive flow: surgical revascularisation of angiographically
moderate coronary stenosis is associated with a higher risk
of graft dysfunction in arterial grafts compared with SVGs.
[12, 55, 56]. Therefore, before choosing an arterial revas-
cularisation strategy, careful functional characterisation by
fractional flow reserve of a borderline stenosis should be
considered.
Conclusions
The therapeutic use of LIMA in patients with MVCAD
is the best performing arterial-coronary conduit compared
with other arterial or venous grafts, measured both in pa-
tency and in clinical outcome. Moreover, because of its
distinct physiological properties, it seems to have a healing
effect on distal atherosclerosis, although this effect needs
further elaboration. Furthermore we described the superior-
ity of different arterial grafts compared with venous grafts,
although the latter are still the most frequently used in many
centres. If the graft choice as strategic issue is incorporated
into heart team discussions more appropriate use of arterial
grafts can be expected. What is interesting is the upcom-
ing hybrid strategy after decades of a dichotomic evaluation
and comparison of CABG and PCI in patients with triple-
vessel disease. Contemporary decision-making in coronary
revascularisation will be more than a simple choice be-
tween knife or balloon, and an elaborate choice of conduit
and strategy is part of that.
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